Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

• Main Authors: Hong Zhu (Author), Jingmin Zhu (Author), Yingyu Zhou (Author), Linghan Shan (Author), Cui Li (Author), Yu Cui (Author), Zheng Kang (Author), Mingli Jiao (Author), Huan Liu (Author), Lijun Gao (Author), Qunhong Wu (Author), Yanhua Hao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ObjectiveSince 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on the...